Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma
International Immunopharmacology · 2023-02 · 115 · 109684
DOI: 10.1016/j.intimp.2023.109684 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-02. Verfasst von Zhao Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Osteosarcoma is highly aggressive and prone to metastasis, with a poor prognosis. Increasing evidence identified anoikis has a critical effect in tumor metastasis and invasion. However, the prognostic value of anoikis-related genes (ANRGs) in osteosarcoma and their role in the immune landscape of osteosarcoma remain unclear. METHODS: The RNA sequencing and clinical data of patients with osteosarcoma were extracted from the TARGET and GEO databases, and ANRGs were identified from the GeneCards database. Unsupervised clustering analysis was employed to identify anoikis-related patterns. The ESTIMATE, TIMER and ssGSEA algorithms were used to assess the immune microenvironment of different subtypes. A prognostic signature based on the identified ANRGs was constructed via univariate, LASSO and multivariate Cox regression analyses. KEGG, GO and GSEA were used for functional enrichment of genes associated with different risk subtypes. qPCR, WB and IHC were used to validate the expression of candidate genes. RESULTS: Two anoikis-related patterns with distinct clinical features and immune statuses were identified based on prognosis-related ANRGs. Cluster 2 had more active immunogenicity and a better prognosis than Cluster 1. Subsequently, we developed and validated an anoikis prognostic signature demonstrating excellent predictive ability for the prognosis of osteosarcoma. Anoikis risk score was positively associated with osteosarcoma metastasis and was identified as an independent prognostic marker. Additionally, a nomogram was established to predict the 3- and 5-year survival probability of patients with osteosarcoma. Functional enrichment analysis revealed that immune dysregulation was correlated with poor prognosis. Besides, patients in the low-risk group had higher infiltration levels of immune cells and more active immune function than patients in the high-risk group. Drug sensitivity analysis revealed several chemotherapeutic agents for the treatment of different subtypes of osteosarcoma. CONCLUSION: Our study demonstrated the role of ANRGs in osteosarcoma progression, providing insights into clinical decision making in osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
- Department of Orthopaedics, Shenzhen University General Hospital, Shenzhen 518052, China.
- Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China. Electronic address: fanhb@fmmu.edu.cn.
Zitieren
APA
Zhang, Z., Zhu, Z., Fu, J., Liu, X., Mi, Z., Tao, H., & Fan, H. (2023). Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma. International Immunopharmacology, 115, 109684. https://doi.org/10.1016/j.intimp.2023.109684
Vancouver
Zhang Z, Zhu Z, Fu J, Liu X, Mi Z, Tao H, et al. Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma. International Immunopharmacology. 2023;115:109684. doi:10.1016/j.intimp.2023.109684
BibTeX
@article{Zhang2023,
author = {Zhang, Zhao and Zhu, Zhijie and Fu, Jun and Liu, Xincheng and Mi, Zhenzhou and Tao, Huiren and Fan, Hongbin},
title = {Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma},
journal = {International Immunopharmacology},
year = {2023},
volume = {115},
pages = {109684},
doi = {10.1016/j.intimp.2023.109684}
}
EUVIMED